


BIOTECHNOLOGY  
SYSTEMS  
BRANCH



**RAW SEQUENCE LISTING**  
**ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/039,119  
Source: OIP  
Date Processed by STIC: 4/17/02

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER  
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND  
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efb/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

# Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: <u>112</u>
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE		
1 <u>    </u> Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
2 <u>    </u> Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
3 <u>    </u> Misaligned Amino Numbering	The numbering under each 5 <sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
4 <u>    </u> Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
5 <u>    </u> Variable Length	Sequence(s) <u>    </u> contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6 <u>    </u> PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) <u>    </u> . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
7 <u>    </u> Skipped Sequences (OLD RULES)	Sequence(s) <u>    </u> missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped  Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
8 <u>    </u> Skipped Sequences (NEW RULES)	Sequence(s) <u>    </u> missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000	
9 <u>    </u> Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
10 <u>    </u> Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence	
11 <u>    </u> Use of <220>	Sequence(s) <u>4</u> missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
12 <u>    </u> PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13 <u>    </u> Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.	



Comply  
 Date: 04/17/2002  
 Time: 14:12:50

OIFE

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/039,119

DATE: 04/17/2002

TIME: 14:12:50

Input Set : A:\STEM1110-4.ST25.txt

Output Set: N:\CRF3\04172002\J039119.raw

2 <110> APPLICANT: STEM CELL PHARMACEUTICALS, INC.  
 3 TWARDZIK, Daniel R.  
 4 FELKER, Thomas S.  
 5 PERNET, Andre  
 6 PASKELL, Stefan  
 8 <120> TITLE OF INVENTION: TGF-alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF  
 USE THEREFOR  
 10 <130> FILE REFERENCE: STEM1110-4  
 12 <140> CURRENT APPLICATION NUMBER: US 10/039,119  
 13 <141> CURRENT FILING DATE: 2002-01-04  
 15 <150> PRIOR APPLICATION NUMBER: US 09/641,587  
 16 <151> PRIOR FILING DATE: 2000-08-17  
 18 <150> PRIOR APPLICATION NUMBER: US 09/492,935  
 19 <151> PRIOR FILING DATE: 2000-01-27  
 21 <150> PRIOR APPLICATION NUMBER: US 09/387,567  
 22 <151> PRIOR FILING DATE: 1999-08-19  
 24 <160> NUMBER OF SEQ ID NOS: 7  
 26 <170> SOFTWARE: PatentIn version 3.0  
 28 <210> SEQ ID NO: 1  
 29 <211> LENGTH: 50  
 30 <212> TYPE: PRT  
 31 <213> ORGANISM: Homo sapiens  
 33 <400> SEQUENCE: 1  
 35 Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys  
 36 1 5 10 15  
 38 Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys  
 39 20 25 30  
 41 Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu  
 42 35 40 45  
 44 Leu Ala  
 45 50  
 47 <210> SEQ ID NO: 2  
 48 <211> LENGTH: 50  
 49 <212> TYPE: PRT  
 50 <213> ORGANISM: Rattus norvegicus  
 52 <400> SEQUENCE: 2  
 54 Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gln Tyr Cys  
 55 1 5 10 15  
 57 Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Glu Lys Pro Ala Cys  
 58 20 25 30  
 60 Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu  
 61 35 40 45  
 63 Asp Ala  
 64 50

## RAW SEQUENCE LISTING

DATE: 04/17/2002

PATENT APPLICATION: US/10/039,119

TIME: 14:12:50

Input Set : A:\STEM1110-4.ST25.txt

Output Set: N:\CRF3\04172002\J039119.raw

66 <210> SEQ ID NO: 3  
 67 <211> LENGTH: 57  
 68 <212> TYPE: PRT  
 69 <213> ORGANISM: Artificial sequence  
 71 <220> FEATURE:  
 72 <223> OTHER INFORMATION: A modified human TGF-alpha sequence  
 74 <400> SEQUENCE: 3  
 76 Ser Leu Ser Leu Pro Ala Met Val Val Ser His Phe Asn Asp Cys Pro  
 77 1 5 10 15  
 79 Asp Ser His Thr Gln Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val  
 80 20 25 30  
 82 Gln Glu Asp Lys Pro Ala Cys Val Cys His Ser Gly Tyr Val Gly Ala  
 83 35 40 45  
 85 Arg Cys Glu His Ala Asp Leu Leu Ala  
 86 50 55

The type of errors shown exist throughout  
 the Sequence Listing. Please check subsequent  
 sequences for similar errors.

88 <210> SEQ ID NO: 4  
 89 <211> LENGTH: 11  
 90 <212> TYPE: PRT  
 91 <213> ORGANISM: Artificial sequence  
 93 <220> FEATURE:  
 94 <223> OTHER INFORMATION: Artificial peptide sequence  
 96 <220> FEATURE:  
 97 <221> NAME/KEY: VARIANT  
 98 <222> LOCATION: (1)..(10)  
 99 <223> OTHER INFORMATION: Xaa at residue 1, 5, 7 to 9 is independently V, G or A; Xaa

at  
 100 residue 6 is Y or F; and Xaa at residue 10 is R or K  
 102 <400> SEQUENCE: 4

W--> 104 Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys

105 1 5 10

107 <210> SEQ ID NO: 5

108 <211> LENGTH: 7

109 <212> TYPE: PRT

110 <213> ORGANISM: Artificial sequence

112 <220> FEATURE:

113 <223> OTHER INFORMATION: Artificial peptide sequence

115 <220> FEATURE:

116 <221> NAME/KEY: VARIANT

117 <222> LOCATION: (1)..(7)

118 <223> OTHER INFORMATION: Xaa at residue 1 and 4 is E or D; Xaa at residue 3 and 7 is  
 V, G,

119 or A; Xaa at residue 5 is L or I; and Xaa at residue 6 is D or E

122 <400> SEQUENCE: 5

W--> 124 Xaa His Xaa Xaa Xaa Xaa Xaa

125 1 5

127 <210> SEQ ID NO: 6

128 <211> LENGTH: 18

129 <212> TYPE: PRT

130 <213> ORGANISM: Artificial sequence

132 <220> FEATURE:

133 <223> OTHER INFORMATION: Artificial peptide sequence

## RAW SEQUENCE LISTING

DATE: 04/17/2002

PATENT APPLICATION: US/10/039,119

TIME: 14:12:50

Input Set : A:\STEM1110-4.ST25.txt

Output Set: N:\CRF3\04172002\J039119.raw

135 <220> FEATURE:  
 136 <221> NAME/KEY: VARIANT  
 137 <222> LOCATION: (1)..(18)  
 138 <223> OTHER INFORMATION: Xaa at residue 1, 5, 7-9, 14, 18 is indep. V, G, or A; Xaa  
 at  
 139 residue 6 is Y or F; Xaa at residue 10 is R or K; Xaa at residue 12,  
 140 15 is indep. E or D; Xaa at residue 16 is L or I; Xaa at residue  
 141 17 is D or E  
 143 <400> SEQUENCE: 6  
 W--> 145 Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa His Xaa Xaa Xaa  
 146 1 5 10 15  
 W--> 148 Xaa Xaa  
 151 <210> SEQ ID NO: 7  
 152 <211> LENGTH: 7  
 153 <212> TYPE: PRT  
 154 <213> ORGANISM: Artificial sequence  
 156 <220> FEATURE:  
 157 <223> OTHER INFORMATION: Artificial peptide sequence  
 159 <220> FEATURE:  
 160 <221> NAME/KEY: VARIANT  
 161 <222> LOCATION: (1)..(7)  
 162 <223> OTHER INFORMATION: Xaa at residue 1 and 2 is indep. V, G, and A; Xaa at residue  
 7 is  
 163 K or D  
 165 <400> SEQUENCE: 7  
 W--> 167 Xaa Xaa Ser His Phe Asn Xaa  
 168 1 5

## VERIFICATION SUMMARY

DATE: 04/17/2002

PATENT APPLICATION: US/10/039,119

TIME: 14:12:51

Input Set : A:\STEM1110-4.ST25.txt

Output Set: N:\CRF3\04172002\J039119.raw

L:104 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4  
L:124 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:145 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6  
L:148 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6  
L:167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7